Photo by matmacq from unsplash
Immune checkpoint inhibitors targeting the programmed cell death 1 (PD‐1) receptor and its ligand, programmed death ligand 1 (PD‐L1), have emerged as a therapeutic approach for patients with non–small cell… Click to show full abstract
Immune checkpoint inhibitors targeting the programmed cell death 1 (PD‐1) receptor and its ligand, programmed death ligand 1 (PD‐L1), have emerged as a therapeutic approach for patients with non–small cell lung carcinoma (NSCLC). PD‐L1 expression, assessed by immunohistochemistry (IHC), is used to select patients for PD‐1/PD‐L1 inhibitor therapy. Most studies have been performed with histology specimens, with limited data available on the performance in cytology specimens. This study evaluated PD‐L1 in cytology specimens and compared the results with those from paired core‐needle biopsy for concordance.
Journal Title: Cancer Cytopathology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!